PMID: 20388964 Chang CH, et al
This study measured total 25(OH)VD status using an enzyme-linked immunosorbent assay (ELISA) kit
Cell Stem Cell 23 , 544556.e544 (2018)
Addressing the limitations of conventional therapies, DDS offers a three-dimensional therapeutic paradigm through interdisciplinary innovations in material science and pharmacokinetics, particularly for gout and hyperuricemia management ( 3.6.1 Organ-specific targeted delivery Surface-modified nanocarriers (e.g., nanoparticles and liposomes) enable precise drug enrichment in renal proximal tubules or hepatocytes ( 3.6.2 Spatiotemporally controlled sustained-release platforms Microsphere/liposome systems: PLGA- or lipid-encapsulated uricase formulations achieve weeks-to-months sustained release, reducing injection frequency and improving adherence in chronic regimens ( 2 composites) trigger drug release in acidic microenvironments (e.g., inflammation sites and crystal deposits), enhancing local efficacy ( 3.6.3 Multimodal synergistic therapeutics DDS enables urate-lowering + anti-inflammatory combinatorial strategies through co-delivery systems
Composition CJC-1295 (Without DAC): 5 mg Ipamorelin: 5 mg Appearance: Lyophilized powder in a sealed research vial Research Focus (non-clinical) Comparative and combined pathway evaluation of GHRH analog + GHS agonist in in-vitro or ex-vivo models Assessment of assay development, including chromatographic separation of co-formulated peptides Stability characterization of a two-analyte lyophilized blend under laboratory storage conditions Documentation Lot-specific COA available Batch and lot traceability Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA Lyophilized for transit stability
